A systematic review and meta-analysis suggests that girls with idiopathic central precious puberty who are treated with gonadotropin-releasing hormone analogue therapy may expect to have a higher final adult height and lower BMI than if they do not receive the treatment.
A longitudinal study of Finnish patients with juvenile acquired hypothyroidism has revealed that an abnormal growth pattern may be present for up to 5 years before diagnosis.
Children with idiopathic short stature and skeletal deformities should be tested for the NPR2 mutation, recommend Chinese researchers who believe that children with heterozygous mutations may benefit from recombinant human growth hormone therapy.
Watch the webcast that was recorded in São Paolo with regional experts Dr Alexander Jorge and Professor Ana Claudia Latronico. We discussed the translational advances in Latin America and how an improved understanding of the genetics have contributed to the diagnostics and treatment of growth and puberty disorders.
Professor Savage was joined by growth disorder and digital health specialists to address resistant factors to the adoption of technology, and demonstrate how, despite a lack of published data on the efficacy of digital tools, supporting evidence of their effectiveness in other endocrine disorders, such as diabetes, can also be applied to paediatric growth disorder management.
A single measurement of plasma levels of a fragment of type X collagen (Collagen X bioMarker) may give an instant picture of how fast a child is growing, say researchers.
The designation “Idiopathic short stature” was first used in the 1980s as a description for short children who had normal growth hormone secretion and otherwise unexplained short stature.
The C-type natriuretic peptide analogue vosoritide significantly increases the growth rate of children with achondroplasia, indicate the results of a randomised, double-blind phase 3 study published in The Lancet.
Rare copy number variants have been identified in a study of children who have growth hormone insensitivity or insulin-like growth factor-1 insensitivity, shedding light on the genetic basis of their conditions
Dr Cheri Deal discusses the use of growth hormone in children with Prader-Willi syndrome, the importance of multidisciplinary care and the future of treatment for this genetic condition.
